Monit drug9/7/2023 ![]() ![]() Whatever its price, patients may be delayed getting access to Leqembi because of the relative shortage of specialists capable of managing the drug, which will require genetic and neuropsychological testing as well as the PET scan to confirm a patient's eligibility. "Above that range doesn't seem like a good place," he said. In an interview, David Rind, ICER's chief medical officer, said $10,000 to $15,000 a year would be reasonable. In its analysis, ICER suggested that Leqembi could be cost-effective at an annual price of $8,900 to $21,500. He contributed to a study that estimated lecanemab and related care would cost Medicare $2 billion to $5 billion a year, making it one of the most expensive taxpayer-funded treatments. "Real people will be affected," Mafi said. Such increases can be a significant burden for many of the 62 million Medicare subscribers who live on fixed incomes. In anticipation of additional costs from the Leqembi drug class, the Centers for Medicare & Medicaid Services in 2021 increased monthly premiums for Medicare patients by 15%, and premiums may rise again in 2024 after a slight decline this year. The great expense of the drug and its treatment raises questions about how it will be paid for, and who will benefit. Although those side effects usually resolved without obvious harm, they apparently caused three deaths. Patients with early Alzheimer's disease who took lecanemab in a major clinical trial declined an average of five months slower than other subjects over an 18-month period, but many suffered brain swelling and bleeding. About 1 million Alzheimer's patients in the U.S. The FDA gave the drug full approval July 6. taxpayers $82,500 per patient per year, on average, for genetic tests and frequent brain scans, safety monitoring, and other care, according to estimates from the Institute for Clinical and Economic Review, or ICER. In addition to the company's $26,500 annual price tag for the drug, treatment could cost U.S. Medicare and Medicaid patients will make up 92% of the market for lecanemab, according to Eisai Co., which sells the drug under the brand name Leqembi. health care system billions annually even as it remains out of reach for many of the lower-income seniors most likely to suffer from dementia. The first drug purporting to slow the advance of Alzheimer's disease is likely to cost the U.S. FDA fully approves Leqembi, first drug to slow progression of Alzheimer's disease 05:48 ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |